


Attorney Docket No.: PB60602USW

Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Currently Amended) A compound of formula (I):



(I)

wherein A represents an optionally substituted aryl, or an optionally substituted 5- or 6- membered heterocycl ring, or an optionally substituted bicyclic heterocycl group;

B represents a phenyl or pyridyl ring;

Z represents O, S, SO, or SO<sub>2</sub>;

R<sup>1</sup> represents CO<sub>2</sub>R<sup>4</sup>, CN, CONR<sup>5</sup>R<sup>6</sup>, CH<sub>2</sub>CO<sub>2</sub>R<sup>4</sup>, OR<sup>4</sup>, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted SO<sub>2</sub>alkyl, SO<sub>2</sub>NR<sup>5</sup>R<sup>6</sup>, NR<sup>5</sup>CONR<sup>5</sup>R<sup>6</sup>, COalkyl, 2H-tetrazol-5-yl-methyl, optionally substituted bicyclic heterocycle or optionally substituted heterocycl;

R<sup>2a</sup> and R<sup>2b</sup> each independently represents hydrogen, halogen, optionally substituted alkyl, optionally substituted alkoxy, CN, SO<sub>2</sub>alkyl, SR<sup>5</sup>, NO<sub>2</sub>, optionally substituted aryl, CONR<sup>5</sup>R<sup>6</sup> or optionally substituted heteroaryl;

R<sup>x</sup> represents optionally substituted alkyl wherein 1 or 2 of the non-terminal carbon atoms are optionally replaced by a group independently selected from NR<sup>4</sup>, O and SO<sub>n</sub>, wherein n is 0, 1 or 2; or R<sup>x</sup> represents optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-heterocycl, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-bicyclic heterocycl or optionally substituted CQ<sup>a</sup>Q<sup>b</sup>-aryl;

R<sup>4</sup> represents hydrogen or an optionally substituted alkyl;

R<sup>5</sup> represents hydrogen or an optionally substituted alkyl;

Attorney Docket No.: PB60602USW

R<sup>6</sup> represents hydrogen or optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted SO<sub>2</sub>aryl, optionally substituted SO<sub>2</sub>alkyl, optionally substituted SO<sub>2</sub>heteroaryl, CN, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>aryl, optionally substituted CQ<sup>a</sup>Q<sup>b</sup>heteroaryl or COR<sup>7</sup>;

R<sup>7</sup> represents hydrogen, optionally substituted alkyl, optionally substituted heteroaryl or optionally substituted aryl;

R<sup>8</sup> represents hydrogen, Cl, CF<sub>3</sub>, or C<sub>1-3</sub>alkyl;

R<sup>9</sup> represents halogen, hydrogen, CF<sub>3</sub>, or C<sub>1-3</sub>alkyl;

Q<sup>a</sup> and Q<sup>b</sup> are each independently selected from hydrogen and CH<sub>3</sub>; wherein when A is a 6-membered ring the R<sup>1</sup> substituent and pyrrole ring are attached to carbon atoms 1,2-, 1,3- or 1,4- relative to each other, and when A is a five-membered ring or bicyclic heterocyclyl group the R<sup>1</sup> substituent and phenyl ring are attached to substitutable carbon atoms 1,2- or 1,3- relative to each other;

and derivatives thereof.

2. (Original) A compound according to claim 1 wherein A is optionally substituted phenyl, optionally substituted pyridyl or optionally substituted isoquinolinyl.

3. (Canceled).

4. (Currently Amended) A pharmaceutical composition comprising a compound according to ~~any one of~~ claims 1 to 3 or a pharmaceutically acceptable derivative thereof together with a pharmaceutical carrier and/or excipient.

5. (Currently Amended) A compound according to ~~any one of~~ claims 1 to 3 or a pharmaceutically acceptable derivative thereof for use as an active therapeutic substance.

Attorney Docket No.: **PB60602USW**

6. (Currently Amended) A compound according to ~~any one~~ of claims 1 to 3 or a pharmaceutically acceptable derivative thereof for use in the treatment of a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors.
7. (Currently Amended) A method of treating a human or animal subject suffering from a condition which is mediated by the action of PGE<sub>2</sub> at EP<sub>1</sub> receptors which comprises administering to said subject an effective amount of a compound according to ~~any one~~ of claims 1 to 3 or a pharmaceutically acceptable derivative thereof.
8. (Currently Amended) A method of treating a human or animal subject suffering from inflammatory pain, neuropathic pain or visceral pain which method comprises administering to said subject an effective amount of a compound according to ~~any one~~ of claims 1 to 3 or a pharmaceutically acceptable derivative thereof.
9. – 10. (Canceled).